Current status of solvent/detergent-treated frozen plasma

Transfusion

Volumn 38, Issue 1, 1998, Pages 102-107

  Klein, H G ^a,b   Dodd, R Y ^a,c   Dzik, W H ^a,d   Luban, N L ^a,e   Ness, P M ^a,f   Pisciotto, P ^g   Schiff, P D ^h   Snyder, E L ⁱ  

^a American Association of Blood Banks

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c HOLLAND LABORATORY   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^f JOHNS HOPKINS HOSPITAL   (United States)

^g UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^h General Counsel   (United States)

ⁱ YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD TRANSFUSION; CLINICAL PRACTICE; DATA ANALYSIS; DISEASE TRANSMISSION; FOOD AND DRUG ADMINISTRATION; FREEZING; PATIENT COMPLIANCE; PLASMAPHERESIS; PRACTICE GUIDELINE; VIRUS INACTIVATION; VIRUS TRANSMISSION;

EID: 0031938607     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1998.38198141508.x     Document Type: Article

References (28)

1. Blood supply: transfusion-associated risks. GAO/PEMD-97-2. Washington, DC: Government Printing Office, 1997.
2. Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996;334:1685-90.
3. Bowden R, Sayer M. The risk of transmitting cytomegalovirus by fresh frozen plasma. Transfusion 1990;30:762-3.
4. Ragni MV, Tegtmeier GE, Levy JA, et al. AIDS retrovirus antibodies in hemophiliacs treated with factor VIII or factor IX concentrates, cryoprecipitate, or fresh frozen plasma: prevalence, seroconversion rate, and clinical correlations. Blood 1986;67:592-5.
5. Horowitz B, Bonomo R, Prince AM, et al. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992;79:826-31.
6. Prince AM, Horowitz B, Brotman B, et al. Inactivation of hepatitis B and Hutchison strain non-A, non-B hepatitis viruses by exposing to Tween 80 and ether. Vox Sang 1984;46:36-43.
7. Prince AM, Horowitz B, Brotman B. Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate. Lancet 1986;1:706-10.
8. Horowitz B, Wiebe ME, Lippin A, Stryker MH. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion 1985;25:516-22.
9. Horowitz B, Prince AM, Hamman J, Watklevicz C. Viral safety of solvent/detergent-treated blood products. Blood Coagul Fibrinol 1994;5(Suppl 3):S21-S28.
10. Horowitz B. Blood protein derivative viral safety: observations and analysis. Yale J Biol Med 1990;63:361-9.
11. Brettler DB, Alter HJ, Dienstag JL, et al. Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients. Blood 1990;76:254-6.
12. Mannucci PM. Outbreak of hepatitis A among Italian patients with haemophilia (letter; comment). Lancet 1992;339:819.
13. Lawlor E, Johnson Z, Thornton L, Temperley I. Investigation of an outbreak of hepatitis A in Irish haemophilia A patients. Vox Sang 1994;67:18-9; discussion 20.
14. Nowicki MJ, Mosley JW, Koerper MA, et al. Passive antibody to hepatitis A virus in U.S. haemophiliacs. Lancet 1993;341:562.
15. Goudemand J. HAV transmission by factor concentrates in France. Vox Sang 1994;67 (Suppl 1):9-13.
16. Gonzaga A. Hepatitis A virus transmission by blood products. A satellite symposium of the XIV Congress of the International Society of Thrombosis and Haemostasis. Vox Sang 1994;67(Suppl 1):29-30.
17. Evensen SA, Rollag H. Solvent/detergent-treated clotting factors and hepatitis A virus seroconversion. Lancet 1993;341:971-2.
18. Normann A, Graff J, Gerritzen A, et al. Detection of hepatitis A virus RNA in a commercially available factor VIII preparation (letter; comment). Lancet 1992;340:1232-3.
19. McOmish F, Yap PL, Simmonds P, Hart H. Detection of hepatitis A virus (HAV) in coagulation factor concentrates using the polymerase chain reaction. Thromb Haemostas 1993;69:939-43.
20. Williams MD, Cohen BJ, Beddall AC, et al. Transmission of human parvovirus B19 by coagulation factor concentrates. Vox Sang 1990;58:177-81.
21. Pehta JC. Clinical studies with solvent detergent-treated products. Transfus Med Rev 1996;10:303-11.
22. Prowse C, Ludlam CA, Yap PL. Human parvovirus B19 and blood products. Vox Sang 1997:72:1-10.
23. McOmish F, Yap PL, Jordan A, et al. Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction. J Clin Microbiol 1993;31:323-8.
24. Sandmeyer EE, Kirwin CJ Jr. Esters. In: Clayton GD, Clayton FE, eds. Patty's industrial hygiene and toxicology. 3rd ed. Volume 2A, Toxicology. New York: Wiley, 1991:2259-71.
25. Comforth JW, et al. Antituberculous effect of certain surface-active polyoxyethylene ethers in mice. Nature 1951;168:150-2.
26. 21 CFR 601.22.
27. AuBuchon JP, Birkmeyer JD. Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply. JAMA 1994;272:1210-4.
28. ARC and VITEX finalize distribution agreement for solvent/ detergent-treated plasma. AABB Weekly Report 1998;4(1):1-2